Literature DB >> 6812608

Intra-dose variation in plasma protein binding of sodium valproate in epileptic patients.

J J Marty, C J Kilpatrick, R F Moulds.   

Abstract

1 The fluctuations in protein binding of sodium valproate during one dosing interval were studied in five patients stabilized on valproate and taking concurrent anticonvulsant therapy. 2 The patients took their usual morning dose of valproate (400-800 mg) and serial blood samples were collected by venepuncture at 0, 1, 2, 3, 4, and 6 h post-dose. 3 Free valproate was separated from protein bound drug by plasma ultrafiltration and the ultrafiltrate and total plasma valproate concentrations were measured by a gas chromatographic method. 4 The maximum and minimum concentrations in the ultrafiltrates occurred at the same times as in the plasma. However, the percentage fluctuation was always greater in the ultrafiltrates (range 192-412%) compared with the plasma (range 153-374%) due to the concentration-dependent nature of valproate protein binding. 5 If free valproate levels are to be monitored, knowledge of sampling time and dosage history is important for interpretation of the results.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6812608      PMCID: PMC1427619          DOI: 10.1111/j.1365-2125.1982.tb01998.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Distribution of valproate across the interface between blood and cerebrospinal fluid.

Authors:  H H Frey; W Löscher
Journal:  Neuropharmacology       Date:  1978-08       Impact factor: 5.250

2.  Disposition of valproic acid in patients with liver disease.

Authors:  U Klotz; T Rapp; W A Müller
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

3.  Pharmacokinetics and bioavailability of sodium valproate.

Authors:  U Klotz; K H Antonin
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875

4.  Valproic acid: reversibly acting drug?

Authors:  J S Lockard; R H Levy
Journal:  Epilepsia       Date:  1976-12       Impact factor: 5.864

5.  Sodium valproate in the management of intractable epilepsy: comparison with clonazepam.

Authors:  J W Lance; M Anthony
Journal:  Proc Aust Assoc Neurol       Date:  1975

6.  Valproic acid in epilepsy: clinical and pharmacological effects.

Authors:  R H Mattson; J A Cramer; P D Williamson; R A Novelly
Journal:  Ann Neurol       Date:  1978-01       Impact factor: 10.422

7.  Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.

Authors:  R Gugler; G Mueller
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

8.  Disposition of sodium valproate in epileptic patients.

Authors:  E Perucca; G Gatti; G M Frigo; A Crema; S Calzetti; D Visintini
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

9.  Disposition of valproic acid in man.

Authors:  R Gugler; A Schell; M Eichelbaum; W Fröscher; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

10.  Sodium valproate in treatment of epilepsy.

Authors:  P M Jeavons; J E Clark
Journal:  Br Med J       Date:  1974-06-15
View more
  4 in total

1.  Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing.

Authors:  W G Rapeport; A D Mendelow; G French; P MacPherson; E Teasdale; E Agnew; G G Thompson; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

2.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

3.  Analysis of tissue distribution of valproate in guinea-pigs: evidence for its capacity-limited tissue distribution.

Authors:  H Y Yu; Y Z Shen
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

4.  Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy.

Authors:  L Herngren; A Nergårdh
Journal:  J Neurol       Date:  1988-11       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.